UNASYN血清杀菌活性及临床药效的观察  

THE SERUM BACTERICIDAL ACTIVITY INVESTIGATION AND CLINICAL TRIAL OF A NEW ANTIBIOTIC——UNASYN

作　　者：刘又宁[1] 王睿[2] 丁杰[1] 陈良安[1] 李峻享 

机构地区：[1]中国人民解放军总医院呼吸科,北京100853 [2]中国人民解放军医总院临床药学实验室

出　　处：《中国抗生素杂志》1990年第4期291-295,共5页Chinese Journal of Antibiotics

摘　　要：本文从临床及体内杀菌活性两方面观察了Unasyn的抗菌效果。10名健康受试者静脉滴注Unasyn 3克(含氨苄青霉素 2克,舒巴克坦 1克),对产酶金葡球菌、变形杆菌、不动杆菌和肺炎杆菌等血清杀菌活性显著高于氨苄青霉素 2克。 Unasyn 6克/日( 5～ 7天)静脉注射用于11名呼吸系感染患者,总有效率90.9％,对肝、肾、凝血功能等无不良影响。The Serum bactericdal activity (SBA) was studied in ten health volunteers receiving Ampicillin 2 g or Unaszn 3g(containing AmpicilJin 2g and Sulbactam lg) given iv.SBA of Unasyn against the strains of S. aureus,P. mirabilis, Acineto-bacter calocaceticus and K, pneumonia were significantly higher than Ampicillin. Eleven patients suffered from pneumonia or airway infection were treated by Una-syn. The total efficacy rate was 90.9%, and no toxicity was found in liver kidney and in blood coagulation mechanism.

关 键 词：UNASYN 血清杀菌活性 临床药效 

分 类 号：R969.4[医药卫生—药理学]